文献速递肝病

MRE联合FIB-4(MEFIB)指数用于识别NASH相关纤维化药物治疗候选者

MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
PubMed 文献 · Gut · 2020-11-19

本研究为前瞻性队列的横断面分析,纳入238例经活检证实的NAFLD患者,评估MRE联合FIB-4诊断≥2期纤维化的准确性。MRE的AUROC为0.93,FIB-4为0.78;联合标准(MRE≥3.3 kPa且FIB-4≥1.6)在训练队列的PPV为97.1%,在日本验证队列(N=222)的PPV为91.0%。MEFIB指数可用于无创识别≥2期纤维化的药物治疗候选者。

要点

  • MRE诊断≥2期纤维化的AUROC为0.93,显著优于FIB-4的0.78。
  • MEFIB联合标准(MRE≥3.3 kPa且FIB-4≥1.6)在训练队列PPV为97.1%。
  • MEFIB在日本验证队列PPV为91.0%,AUROC为0.84。

核心结论

  • MRE联合FIB-4(MEFIB)指数可能用于无创识别NAFLD中≥2期纤维化的药物治疗候选者,具有高阳性预测值。

研究设计与样本

  • 前瞻性队列(UCSD-NAFLD)的横断面分析,纳入238例连续患者,均有同期MRE和活检证实的NAFLD;组织学采用NASH-CRN评分系统,放射科和病理科医生相互盲法。
  • 独立验证队列来自日本横滨市立大学(Japan-NAFLD队列),共222例患者。

主要发现

  • 在UCSD-NAFLD训练队列中,MRE检测≥2期纤维化的AUROC为0.93(95%CI 0.90-0.97),FIB-4的AUROC为0.78(95%CI 0.71-0.85),差异有临床和统计学意义(p<0.0001)。
  • MEFIB联合标准(MRE≥3.3 kPa且FIB-4≥1.6)在UCSD-NAFLD队列的PPV为97.1%(p<0.02),AUROC为0.90(95%CI 0.85-0.95)。
  • 在日本-NAFLD验证队列中,MEFIB的PPV为91.0%(p<0.003),AUROC为0.84(95%CI 0.78-0.89)。

关键数值与推荐

  • MEFIB阳性标准:MRE≥3.3 kPa且FIB-4≥1.6,用于rule in ≥2期纤维化。
  • 训练队列中MEFIB的PPV为97.1%(p<0.02),验证队列PPV为91.0%(p<0.003)。

临床怎么用

  • 对于NAFLD患者,可采用MRE联合FIB-4(MEFIB指数)无创识别≥2期纤维化的药物治疗候选者,高PPV有助于避免不必要的肝活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with non-alcoholic fatty liver disease (NAFLD) with ≥stage 2 fibrosis are at increased risk for liver-related mortality and are candidates for pharmacological therapies for treatment of NAFLD. The aim of this prospective cohort study is to examine the diagnostic accuracy of MR elastography (MRE) combined with fibrosis-4 (FIB-4) in diagnosing ≥stage 2 fibrosis (candidates for pharmacological therapies). DESIGN: This is a cross-sectional analysis of a prospective cohort (University of California at San Diego (UCSD)-NAFLD) including 238 consecutive patients with contemporaneous MRE and biopsy-proven NAFLD. Non-alcoholic steatohepatitis-Clinical Research Network-Histologic Scoring System was used to assess histology. The radiologist and pathologist were blinded to clinical, pathological and imaging data, respectively. Receiver operating characteristics (ROCs) were determined to examine the diagnostic accuracy of MRE and FIB-4 for diagnosis of ≥stage 2 fibrosis in NAFLD. We then validated these findings in an independent validation cohort derived from Yokohama City University in Japan (Japan-NAFLD Cohort; N=222 patients). RESULTS: In the UCSD-NAFLD (training) Cohort, MRE demonstrated a clinically significant diagnostic accuracy for the detection of ≥stage 2 fibrosis with an area under the ROC curve (AUROC) of 0.93 (95% CI 0.90 to 0.97) vs FIB-4 with an AUROC of 0.78 (95% CI 0.71 to 0.85), which was both clinically and statistically significant (p<0.0001). We then combined MRE with FIB-4 (MRE ≥3.3 kPa and FIB-4 ≥1.6) to develop a clinical prediction rule to rule in ≥stage 2 fibrosis patients which had positive predictive value (PPV) of 97.1% (p<0.02) in the UCSD-NAFLD cohort (AUROC of 0.90 (95% CI 0.85 to 0.95)) which remained significant at PPV of 91.0% (p<0.003) in the Japan-NAFLD Cohort (AUROC of 0.84 (95% CI 0.78 to 0.89)). CONCLUSION: MRE combined with FIB-4 (MEFIB) index may be used for non-invasive identification of candidates for (≥stage 2 fibrosis) pharmacological therapy among patients with NAFLD with a high PPV.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut. 2020. PMID: 33214165. doi:10.1136/gutjnl-2020-322976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。